 The study is a non-blinded randomised controlled trial. To assist with recruitment numbers, and assess the feasibility of running a multi-centre trial, we are planning to run this study in several hospitals. Women who have developed HDP requiring medication will be approached during the antenatal period: they will complete an informed consent form and undertake a screening appointment. Following birth, whilst they remain in hospital, consent will be confirmed and a baseline appointment will take place. At this visit women will be randomised to one of two treatment arms: usual care, or self-management. 